|
Delaware
|
| |
91-1707622
|
|
|
(State or Other Jurisdiction
of Incorporation or Organization) |
| |
(I.R.S. Employer
Identification No.) |
|
|
200 Connell Drive
Suite 1500 Berkeley Heights, New Jersey |
| |
07922
|
|
|
(Address of principal executive offices)
|
| |
(Zip Code)
|
|
|
Title of each class
|
| |
Name of each exchange on which registered
|
|
|
Common Stock, $0.001 par value
|
| |
The NASDAQ Stock Market LLC
|
|
|
Preferred Stock, $0.001 par value
|
| |
The NASDAQ Stock Market LLC
|
|
|
Large accelerated filer ☐
|
| |
Accelerated filer ☐
|
|
|
Non-accelerated filer ☒
|
| |
Smaller reporting company ☒
|
|
| | |
Page
|
| |||
PART I
|
| | | | | | |
| | | | 1 | | | |
| | | | 20 | | | |
| | | | 48 | | | |
| | | | 48 | | | |
| | | | 48 | | | |
| | | | 48 | | | |
PART II
|
| | | | | | |
| | | | 49 | | | |
| | | | 49 | | | |
| | | | 49 | | | |
| | | | 58 | | | |
| | | | 59 | | | |
| | | | 86 | | | |
| | | | 86 | | | |
| | | | 87 | | | |
PART III
|
| | | | | | |
| | | | 88 | | | |
| | | | 88 | | | |
| | | | 88 | | | |
| | | | 88 | | | |
| | | | 88 | | | |
PART IV
|
| | | | | | |
| | | | 88 | | |
PROGRAM
|
| |
INDICATION
|
| |
DEVELOPMENT STATUS
|
| |
COMMERCIAL
RIGHTS |
|
Transcriptional Regulation | | | | | | | | | | |
CYC065 CDK inhibitor | | |
Solid Tumors incl. Mcl-1, MYC family, Cyclin E amplification
|
| |
Phase 1 part 2 (ongoing)
|
| |
Worldwide
|
|
| | |
CLL combination with venetoclax, Bcl-2 inhibitor
|
| |
Phase 1 (ongoing)
|
| |
Worldwide
|
|
DNA Damage Response | | | | | | | | | | |
Sapacitabine and seliciclib CDK inhibitor | | |
BRCA mutation positive breast, ovarian, pancreatic cancer
|
| |
Phase 1 part 3 (ongoing)
|
| |
Worldwide (except Japan)
|
|
Sapacitabine and olaparib PARP inhibitor | | |
BRCA mutation positive breast cancer
|
| |
Phase 1 (ongoing investigator-sponsored study)
|
| |
Worldwide (except Japan)
|
|
Sapacitabine in AML Phase 3 SEAMLESS study | | |
AML ≥70 years unfit for or refused intensive chemotherapy
|
| |
Phase 3 completed(subgroup analysis)
|
| |
Worldwide(except Japan)
|
|
Mitosis Regulation | | | | | | | | | | |
CYC140 PLK inhibitor | | |
Advanced leukemias
|
| |
Phase 1 (ongoing)
|
| |
Worldwide
|
|
| | |
PART 1
|
| |
PART 2
|
| ||||||||||||||||||
| | |
BRCA carriers
(n=16) |
| |
Others
(n=22) |
| |
BRCA carriers
(n=28) |
| |
Others
(n=1) |
| ||||||||||||
CR | | | | | 1 | | | | | | — | | | | | | — | | | | | | — | | |
PR | | | | | 3 | | | | | | — | | | | | | 2 | | | | | | — | | |
SD | | | | | 2 | | | | | | 6 | | | | | | 7 | | | | | | 1* | | |
ORR (CR/PR)
|
| | | | 25% | | | | | | 0% | | | | | | 7% | | | | | | 0% | | |
Disease Control (CR/PR/SD)
|
| | | | 6 (37.5)% | | | | | | 6 (27.3)% | | | | | | 9 (32.1)% | | | | | | 1 (100.0)% | | |
|
| | |
Year ended December 31,
|
| |
Difference
|
| ||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
$
|
| |
%
|
| ||||||||||||
Grant revenue
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | | | | | — | | |
Collaboration and research and development revenue
|
| | | | — | | | | | | 150 | | | | | | 150 | | | | | | 100 | | |
Total Revenue
|
| | | $ | — | | | | | $ | 150 | | | | | $ | 150 | | | | | | 100 | | |
|
| | |
Year ended December 31,
|
| |
Difference
|
| ||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
$
|
| |
%
|
| ||||||||||||
Transcriptional Regulation (CYC065)
|
| | | $ | 1,057 | | | | | $ | 2,522 | | | | | $ | 1,465 | | | | | | 139 | | |
DNA Damage Response (sapacitabine and seliciblib)
|
| | | | 364 | | | | | | 43 | | | | | | (321) | | | | | | (88) | | |
Sapacitabine (SEAMLESS and manufacturing)
|
| | | | 2,504 | | | | | | 814 | | | | | | (1,690) | | | | | | (67) | | |
Other research and development programs and expenses
|
| | | | 312 | | | | | | 948 | | | | | | 636 | | | | | | 204 | | |
Total research and development
|
| | | $ | 4,237 | | | | | $ | 4,327 | | | | | $ | 90 | | | | | | 2 | | |
|
| | |
Year ended December 31,
|
| |
Difference
|
| ||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
$
|
| |
%
|
| ||||||||||||
General and administrative
|
| | | $ | 5,254 | | | | | $ | 5,371 | | | | | $ | 117 | | | | | | 2 | | |
Total General and administrative
|
| | | $ | 5,254 | | | | | $ | 5,371 | | | | | $ | 117 | | | | | | 2 | | |
|
| | |
Year ended December 31,
|
| |
Difference
|
| ||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
$
|
| |
%
|
| ||||||||||||
Foreign exchange losses
|
| | | $ | (39) | | | | | $ | (90) | | | | | $ | (51) | | | | | | (131) | | |
Interest income
|
| | | | 118 | | | | | | 331 | | | | | | 213 | | | | | | 181 | | |
Other income, net
|
| | | | 949 | | | | | | 682 | | | | | | (267) | | | | | | (28) | | |
Total other income, net
|
| | | $ | 1,028 | | | | | $ | 923 | | | | | $ | (105) | | | | | | (10) | | |
|
| | |
Year ended December 31,
|
| |
Difference
|
| ||||||||||||||||||
| | |
2017
|
| |
2018
|
| |
$
|
| |
%
|
| ||||||||||||
Income tax benefit
|
| | | $ | 993 | | | | | $ | 1,337 | | | | | $ | 344 | | | | | | 35 | | |
Total Income tax benefit
|
| | | $ | 993 | | | | | $ | 1,337 | | | | | $ | 344 | | | | | | 35 | | |
|
| | |
Year ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Cash and cash equivalents
|
| | | $ | 23,910 | | | | | $ | 17,504 | | |
Working capital: | | | | | | | | | | | | | |
Current assets
|
| | | | 25,974 | | | | | | 19,787 | | |
Current liabilities
|
| | | | (4,113) | | | | | | (4,450) | | |
Total working capital
|
| | | $ | 21,861 | | | | | $ | 15,337 | | |
|
| | |
Year Ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Net cash used in operating activities
|
| | | $ | (7,480) | | | | | $ | (6,701) | | |
Net cash used in investing activities
|
| | | | (13) | | | | | | (39) | | |
Net cash provided by financing activities
|
| | | | 14,748 | | | | | | 429 | | |
| | |
Payments Due by Period
|
| |||||||||||||||||||||||||||
| | |
Total
|
| |
Less than
1 year |
| |
1 – 3 years
|
| |
3 – 5 years
|
| |
More than
5 years |
| |||||||||||||||
Operating Lease Obligation(1)
|
| | | $ | 2,201 | | | | | $ | 325 | | | | | $ | 650 | | | | | $ | 645 | | | | | $ | 581 | | |
| | |
Page
|
| |||
| | | | 60 | | | |
Consolidated Balance Sheets as of December 31, 2017 and 2018
|
| | | | 61 | | |
| | | | 62 | | | |
| | | | 63 | | | |
| | | | 64 | | | |
| | | | 65 | | | |
| | | | 66 | | |
| | |
December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 23,910 | | | | | $ | 17,504 | | |
Prepaid expenses and other current assets
|
| | | | 2,064 | | | | | | 2,283 | | |
Total current assets
|
| | | | 25,974 | | | | | | 19,787 | | |
Property and equipment, net
|
| | | | 29 | | | | | | 36 | | |
Total assets
|
| | | $ | 26,003 | | | | | $ | 19,823 | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 1,558 | | | | | $ | 2,719 | | |
Accrued and other current liabilities
|
| | | | 2,555 | | | | | | 1,732 | | |
Total current liabilities
|
| | | | 4,113 | | | | | | 4,451 | | |
Other liabilities
|
| | | | 124 | | | | | | 100 | | |
Total liabilities
|
| | | | 4,237 | | | | | | 4,551 | | |
Commitments and contingencies (Notes 3 and 9) | | | | | | | | | | | | | |
Stockholders’ equity: | | | | | | | | | | | | | |
Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2017 and December 31, 2018
|
| | | | | | | | | | | | |
6% Convertible Exchangeable preferred stock; 335,273 shares issued and outstanding at December 31, 2017 and December 31, 2018. Aggregate preference in liquidation of $4,006,512 at December 31, 2017 and December 31, 2018
|
| | | | — | | | | | | — | | |
Series A convertible preferred stock; 264 shares issued and outstanding at December 31, 2017 and December 31, 2018
|
| | | | — | | | | | | — | | |
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2017 and December 31, 2018; 11,997,447 and 12,497,447 shares issued and outstanding at December 31, 2017 and December 31, 2018, respectively
|
| | | | 12 | | | | | | 12 | | |
Additional paid-in capital
|
| | | | 365,057 | | | | | | 365,817 | | |
Accumulated other comprehensive loss
|
| | | | (794) | | | | | | (760) | | |
Accumulated deficit
|
| | | | (342,509) | | | | | | (349,797) | | |
Total stockholders’ equity
|
| | | | 21,766 | | | | | | 15,272 | | |
Total liabilities and stockholders’ equity
|
| | | $ | 26,003 | | | | | $ | 19,823 | | |
|
| | |
Year Ended December 31,
|
||||||||
| | |
2017
|
| |
2018
|
|||||
Revenues: | | | | | | | | | | | |
Collaboration and research and development revenue
|
| | | $ | — | | | | | $ | 150 |
Operating expenses: | | | | | | | | | | | |
Research and development
|
| | | | 4,237 | | | | | | 4,327 |
General and administrative
|
| | | | 5,254 | | | | | | 5,371 |
Total operating expenses
|
| | | | 9,491 | | | | | | 9,698 |
Operating loss
|
| | | | (9,491) | | | | | | (9,548) |
Other income (expense): | | | | | | | | | | | |
Foreign exchange losses
|
| | | | (39) | | | | | | (90) |
Interest income
|
| | | | 118 | | | | | | 331 |
Other income, net
|
| | | | 949 | | | | | | 682 |
Total other income (expense), net
|
| | | | 1,028 | | | | | | 923 |
Loss from continuing operations before taxes
|
| | | | (8,463) | | | | | | (8,625) |
Income tax benefit
|
| | | | 993 | | | | | | 1,337 |
Net loss
|
| | | | (7,470) | | | | | | (7,288) |
Dividend on convertible exchangeable preferred shares
|
| | | | (201) | | | | | | (201) |
Beneficial conversion feature of Series A convertible stock
|
| | | | (3,638) | | | | | | — |
Conversion of Series A convertible preferred stock
|
| | | | (3,537) | | | | | | — |
Net loss applicable to common shareholders
|
| | | $ | (14,846) | | | | | $ | (7,489) |
Basic and diluted earnings per common share: | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (1.95) | | | | | $ | (0.62) |
Weighted average common shares outstanding
|
| | | | 7,631,152 | | | | | | 12,094,131 |
|
| | |
Year Ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Net loss
|
| | | $ | (7,470) | | | | | $ | (7,288) | | |
Translation adjustment
|
| | | | (14,687) | | | | | | 9,370 | | |
Unrealized foreign exchange gain (loss) on intercompany loans
|
| | | | 14,636 | | | | | | (9,336) | | |
Comprehensive loss
|
| | | $ | (7,521) | | | | | $ | (7,254) | | |
|
| | |
P Preferred Stock
|
| |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity |
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balances at December 31, 2016
|
| | | | 335,273 | | | | | $ | — | | | | | | 4,256,829 | | | | | $ | 4 | | | | | $ | 350,051 | | | | | $ | (743) | | | | | $ | (335,039) | | | | | $ | 14,273 | | |
Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses
|
| | | | 8,872 | | | | | | — | | | | | | 3,154,000 | | | | | | 3 | | | | | | 13,681 | | | | | | — | | | | | | — | | | | | | 13,684 | | |
Series A Preferred stock conversions
|
| | | | (8,608) | | | | | | — | | | | | | 4,304,000 | | | | | | 4 | | | | | | (4) | | | | | | — | | | | | | — | | | | | | — | | |
Warrant exercise
|
| | | | — | | | | | | — | | | | | | 99,500 | | | | | | — | | | | | | 199 | | | | | | — | | | | | | — | | | | | | 199 | | |
Issue of common stock on At Market
Issuance sales agreement |
| | | | — | | | | | | — | | | | | | 183,118 | | | | | | — | | | | | | 1,066 | | | | | | — | | | | | | — | | | | | | 1,066 | | |
Stock-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 266 | | | | | | — | | | | | | — | | | | | | 266 | | |
Preferred stock dividends
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (201) | | | | | | — | | | | | | — | | | | | | (201) | | |
Unrealized foreign exchange on intercompany loans
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 14,636 | | | | | | — | | | | | | 14,636 | | |
Translation adjustment
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (14,687) | | | | | | — | | | | | | (14,687) | | |
Loss for the period
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (7,470) | | | | | | (7,470) | | |
Balances at December 31, 2017
|
| | | | 335,537 | | | | | $ | — | | | | | | 11,997,447 | | | | | $ | 12 | | | | | $ | 365,057 | | | | | $ | (794) | | | | | $ | (342,509) | | | | | $ | 21,766 | | |
Issue of common stock on
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
At Market Issuance sales agreement
|
| | | | — | | | | | | — | | | | | | 500,000 | | | | | | — | | | | | | 630 | | | | | | — | | | | | | — | | | | | | 630 | | |
Stock-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 331 | | | | | | — | | | | | | — | | | | | | 331 | | |
Preferred stock dividends
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (201) | | | | | | — | | | | | | — | | | | | | (201) | | |
Unrealized foreign exchange on intercompany loans
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (9,336) | | | | | | — | | | | | | (9,336) | | |
Translation adjustment
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,370 | | | | | | — | | | | | | 9,370 | | |
Loss for the period
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (7,288) | | | | | | (7,288) | | |
Balances at December 31, 2018
|
| | | | 335,537 | | | | | $ | — | | | | | | 12,497,447 | | | | | $ | 12 | | | | | $ | 365,817 | | | | | $ | (760) | | | | | $ | (349,797) | | | | | $ | 15,272 | | |
|
| | |
Year Ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (7,470) | | | | | $ | (7,288) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Depreciation expense
|
| | | | 32 | | | | | | 29 | | |
Stock-based compensation expense
|
| | | | 266 | | | | | | 331 | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | |
Prepaid expenses and other assets
|
| | | | 1,232 | | | | | | (327) | | |
Accounts payable and other current liabilities
|
| | | | (1,540) | | | | | | 554 | | |
Net cash used in operating activities
|
| | | | (7,480) | | | | | | (6,701) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Purchases of property and equipment
|
| | | | (13) | | | | | | (39) | | |
Net cash used in investing activities
|
| | | | (13) | | | | | | (39) | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from issuance of equity securities, net of issuance costs
|
| | | | 14,749 | | | | | | 630 | | |
Proceeds from the exercise of stock options and warrants, net of issuance costs
|
| | | | 200 | | | | | | — | | |
Payment of preferred stock dividend
|
| | | | (201) | | | | | | (201) | | |
Net cash provided by financing activities
|
| | | | 14,748 | | | | | | 429 | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | 135 | | | | | | (95) | | |
Net increase/(decrease) in cash and cash equivalents
|
| | |
|
7,390
|
| | | |
|
(6,406)
|
| |
Cash and cash equivalents at beginning of period
|
| | | | 16,520 | | | | | | 23,910 | | |
Cash and cash equivalents at end of period
|
| | | $ | 23,910 | | | | | $ | 17,504 | | |
Supplemental cash flow information: | | | | | | | | | | | | | |
Cash received during the period for: | | | | | | | | | | | | | |
Interest
|
| | | | 118 | | | | | | 331 | | |
Taxes
|
| | | | 1,815 | | | | | | 1,158 | | |
Non cash financing activities: | | | | | | | | | | | | | |
Accrual of preferred stock dividends
|
| | | | 50 | | | | | | 50 | | |
| | |
December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Cash
|
| | | $ | 1,103 | | | | | $ | 816 | | |
Investments with original maturity of less than three months at the time of purchase
|
| | | | 22,807 | | | | | | 16,688 | | |
Total cash and cash equivalents
|
| | | $ | 23,910 | | | | | $ | 17,504 | | |
|
| | |
Fair Value Measurements
as of December 31, 2017 Using: |
| | ||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Assets: | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash equivalents
|
| | | $ | 22,807 | | | | | $ | — | | | | | $ | — | | | | | $ | 22,807 | | |
Total Assets
|
| | | $ | 22,807 | | | | | $ | — | | | | | $ | — | | | | | $ | 22,807 | | |
|
| | |
Fair Value Measurements
as of December 31, 2018 Using: |
| | ||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Assets: | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash equivalents
|
| | | $ | 16,688 | | | | | $ | — | | | | | $ | — | | | | | $ | 16,688 | | |
Total Assets
|
| | | $ | 16,688 | | | | | $ | — | | | | | $ | — | | | | | $ | 16,688 | | |
|
| | |
December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Research and development tax credit receivable
|
| | | $ | 1,054 | | | | | $ | 1,148 | | |
Prepayments
|
| | | | 363 | | | | | | 543 | | |
VAT receivable
|
| | | | 409 | | | | | | 356 | | |
Deposits
|
| | | | 132 | | | | | | 66 | | |
Other current assets
|
| | | | 106 | | | | | | 170 | | |
Prepaid expenses and other current assets
|
| | | $ | 2,064 | | | | | $ | 2,283 | | |
|
| | |
Lives in years
|
| |
December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| |||||||||
Leasehold improvements
|
| |
5 to 15
|
| | | $ | 835 | | | | | $ | 807 | | |
Research and laboratory equipment
|
| |
3 to 5
|
| | | | 4,854 | | | | | | 4,209 | | |
Office equipment and furniture
|
| |
3 to 5
|
| | | | 1,236 | | | | | | 1,140 | | |
| | | | | | | | 6,925 | | | | | | 6,156 | | |
Less: accumulated depreciation and amortization
|
| | | | | | | (6,896) | | | | | | (6,120) | | |
| | | | | | | $ | 29 | | | | | $ | 36 | | |
|
| | |
December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Accrued research and development
|
| | | $ | 1,645 | | | | | $ | 1,110 | | |
Accrued legal and professional fees
|
| | | | 248 | | | | | | 259 | | |
Other current liabilities
|
| | | | 662 | | | | | | 363 | | |
| | | | $ | 2,555 | | | | | $ | 1,732 | | |
|
| | |
Operating Lease
Obligation |
| |||
2019
|
| | | $ | 321 | | |
2020
|
| | | | 321 | | |
2021
|
| | | | 321 | | |
2022
|
| | | | 321 | | |
2023
|
| | | | 321 | | |
thereafter
|
| | | | 581 | | |
Total future minimum lease obligations
|
| | | $ | 2,186 | | |
|
| | |
Year Ended
December 31, 2017 |
| |
Year Ended
December 31, 2018 |
| ||||||
Research and development
|
| | | $ | 72 | | | | | $ | 88 | | |
General and administrative
|
| | | | 194 | | | | | | 243 | | |
Stock-based compensation costs before income taxes
|
| | | $ | 266 | | | | | $ | 331 | | |
|
| | |
Number of
Options Outstanding |
| |
Weighted
Average Exercise Price Per Share |
| |
Weighted
Average Remaining Contractual Term (Years) |
| |
Aggregate
Intrinsic Value ($000s) |
| ||||||||||||
Options outstanding at December 31, 2016
|
| | | | 389,379 | | | | | $ | 25.80 | | | | | | 5.83 | | | | | $ | 121 | | |
Granted
|
| | | | 170,853 | | | | | $ | 1.93 | | | | | | | | | | | | | | |
Exercised
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Cancelled/forfeited
|
| | | | (24,615) | | | | | $ | 179.92 | | | | | | | | | | | | | | |
Options outstanding at December 31, 2017
|
| | | | 535,617 | | | | | $ | 11.10 | | | | | | 8.23 | | | | | $ | — | | |
Granted
|
| | | | 306,304 | | | | | $ | 1.51 | | | | | | | | | | | | | | |
Exercised
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Cancelled/forfeited
|
| | | | (10,310) | | | | | $ | 82.38 | | | | | | | | | | | | | | |
Options outstanding at December 31, 2018
|
| | | | 831,611 | | | | | $ | 6.68 | | | | | | 8.13 | | | | | $ | — | | |
Unvested at December 31, 2018
|
| | | | 573,830 | | | | | $ | 2.57 | | | | | | 8.59 | | | | | $ | — | | |
Vested and exercisable at December 31, 2018
|
| | | | 257,781 | | | | | $ | 15.84 | | | | | | 7.10 | | | | | $ | — | | |
|
| | |
Year ended
December 31, 2017 |
| |
Year ended
December 31, 2018 |
|
Expected term (years)
|
| |
6
|
| |
6
|
|
Risk free interest rate
|
| |
1.890% – 2.265%
|
| |
2.730% – 2.855%
|
|
Volatility
|
| |
108%
|
| |
105% – 107%
|
|
Expected dividend yield over expected term
|
| |
0.00%
|
| |
0.00%
|
|
Resulting weighted average grant date fair value
|
| |
$1.59
|
| |
$1.25
|
|
| | |
Year Ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Domestic
|
| | | $ | (127) | | | | | $ | 20 | | |
Foreign
|
| | | | (8,336) | | | | | | (8,645) | | |
Loss from continuing operations before taxes
|
| | | $ | (8,463) | | | | | $ | (8,625) | | |
|
| | |
Year Ended December 31,
|
| |||||||||
| | |
2017
|
| |
2018
|
| ||||||
Current – domestic
|
| | | $ | — | | | | | $ |